within Pharmacolibrary.Drugs.ATC.C;

model C10AB08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Ciprofibrate is a lipid-lowering agent of the fibrate class, used mainly for the treatment of hyperlipidemia, particularly hypertriglyceridemia. It acts primarily by activating peroxisome proliferator-activated receptors (PPARs), leading to altered lipid metabolism. While previously used and approved in many countries, its usage has declined, and it is withdrawn or not widely used in some regions today.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Eason, CT, et al., &amp; Bonner, FW (1989). The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 19(8) 913–925. DOI:<a href=&quot;https://doi.org/10.3109/00498258909043151&quot;>10.3109/00498258909043151</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2815833/&quot;>https://pubmed.ncbi.nlm.nih.gov/2815833</a></p></li><li><p>Lozada, A, &amp; Dujovne, CA (1994). Drug interactions with fibric acids. <i>Pharmacology &amp; therapeutics</i> 63(2) 163–176. DOI:<a href=&quot;https://doi.org/10.1016/0163-7258(94)90043-4&quot;>10.1016/0163-7258(94)90043-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7809177/&quot;>https://pubmed.ncbi.nlm.nih.gov/7809177</a></p></li><li><p>Miller, DB, &amp; Spence, JD (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). <i>Clinical pharmacokinetics</i> 34(2) 155–162. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199834020-00003&quot;>10.2165/00003088-199834020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9515185/&quot;>https://pubmed.ncbi.nlm.nih.gov/9515185</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C10AB08;
